in Nebraska for the purpose of enhancing the species’ survival.

National Environmental Policy Act

The proposed activities in the requested permits qualify as categorical exclusions under the National Environmental Policy Act, as provided by Department of the Interior implementing regulations in part 46 of title 43 of the Code of Federal Regulations (43 CFR 46.205, 46.210, and 46.215).

Public Availability of Comments

All comments and materials we receive in response to these requests will be available for public inspection, by appointment, during normal business hours at the address listed in the ADDRESSES section of this notice.

Before including your address, phone number, email address, or other personal identifying information in your comment, you should be aware that your entire comment—including your personal identifying information—may be made publicly available at any time. While you can ask us in your comment to withhold your personal identifying information from public review, we cannot guarantee that we will be able to do so.

Authority

We provide this notice under section 10 of the Act (16 U.S.C. 1531 et seq.).

Michael G. Thabault,
Assistant Regional Director, Mountain-Prairie Region.

[FR Doc. 2016–12000 Filed 5–19–16; 8:45 am]

BILLING CODE 4310–33–P

DEPARTMENT OF THE INTERIOR

Bureau of Land Management

[LLORB00000.L17110000.PH0000.LXSSH1060000.16XL1109AF; HAG 16–0136]

Notice of Public Meeting for the Steens Mountain Advisory Council

AGENCY: Bureau of Land Management, Interior.

ACTION: Notice of public meeting.

SUMMARY: In accordance with the Federal Land Policy and Management Act and the Federal Advisory Committee Act of 1972, and the U.S. Department of the Interior, Bureau of Land Management (BLM), the Steens Mountain Advisory Council (SMAC) will meet as indicated below:

DATES: Monday, June 20, 2016 from 8 a.m. to 5 p.m. for an all-day field tour on the east side of Steens Mountain, and Tuesday, June 21, 2016 from 8:30 a.m. to 12 p.m., at the Frenchglen School, Frenchglen, Oregon. Daily sessions may end early if all business items are accomplished ahead of schedule, or go longer if discussions warrant more time.

FOR FURTHER INFORMATION CONTACT: Tara Thissell, Public Affairs Specialist, BLM Burns District Office, 28910 Highway 20 West, Hines, Oregon 97738, (541) 573–4519, or email tthissell@blm.gov. Persons who use a telecommunications device for the deaf (TDD) may call the Federal Information Relay Service (FIRS) at 1(800) 877–8339 to contact the above individual during normal business hours. The FIRS is available 24 hours a day, 7 days a week, to leave a message or question with the above individual. You will receive a reply during normal business hours.

SUPPLEMENTARY INFORMATION: The SMAC was initiated August 14, 2001, pursuant to the Steens Mountain Cooperative Management and Protection Act of 2000 (Pub. L. 106–399). The SMAC provides representative counsel and advice to the BLM regarding new and unique approaches to management of the land within the bounds of the Steens Mountain Cooperative Management and Protection Area, recommends cooperative programs and incentives for landscape management that meet human needs, and advises the BLM on maintenance and improvement of the ecological and economic integrity of the area. Agenda items for the June 20 and 21 sessions include: A field tour to Pike Creek, Frog Springs, and other sites on the east side of Steens Mountain; updates from the Designated Federal Official and the Andrews/Steens Resource Area Field Manager; discussions regarding projects for the Steens Mountain Comprehensive Recreation Plan, inholder access, and fencing in the No Livestock Grazing Area; and regular business items such as approving the previous meeting’s minutes, member round-table, and planning the next meeting’s agenda. Any other matters that may reasonably come before the SMAC may also be addressed. The public may attend the field tour but must provide their own transportation. A public comment period is available during the June 21 session. Unless otherwise approved by the SMAC Chair, the public comment period will last no longer than 30 minutes, and each speaker may address the SMAC for a maximum of five minutes. The public is welcome to attend all sessions, including the field tour, but must provide personal transportation.

Rhonda Karges,
Andrews/Steens Resource Area Field Manager.

[FR Doc. 2016–11948 Filed 5–19–16; 8:45 am]

BILLING CODE 4310–33–P

INTERNATIONAL TRADE COMMISSION

[Investigation Nos. 701–TA–558 and 731–TA–1316 (Preliminary)]

1-Hydroxyethylidene-1, 1-Diphosphonic Acid From China; Determinations

On the basis of the record 1 developed in the subject investigations, the United States International Trade Commission ("Commission") determines, pursuant to the Tariff Act of 1930 ("the Act"), that there is a reasonable indication that an industry in the United States is threatened with material injury by reason of imports of 1-hydroxyethylidene-1, 1-diphosphonic acid ("HEDP") from China, provided for in subheading 2931.90.9043 (statistical reporting number 2931.90.9043) of the Harmonized Tariff Schedule of the United States, that are alleged to be sold in the United States at less than fair value ("LTFV") and are allegedly subsidized by the government of China.

Commencement of Final Phase Investigations

Pursuant to section 207.18 of the Commission’s rules, the Commission also gives notice of the commencement of the final phase of its investigations. The Commission will issue a final phase notice of scheduling, which will be published in the Federal Register as provided in section 207.21 of the Commission’s rules, upon notice from the Department of Commerce ("Commerce") of affirmative preliminary determinations in the investigations under sections 703(b) or 733(b) of the Act, or, if the preliminary determinations are negative, upon notice of affirmative final determinations in those investigations under sections 705(a) or 735(a) of the Act. Parties that filed entries of appearance in the preliminary phase of the investigations need not enter a separate appearance for the final phase of the investigations. Industrial users, and, if the merchandise under investigation is sold at the retail level,

---

1 The record is defined in sec. 207.2(f) of the Commission’s Rules of Practice and Procedure (19 CFR 207.2(f)).
representative consumer organizations have the right to appear as parties in Commission antidumping and countervailing duty investigations. The Secretary will prepare a public service list containing the names and addresses of all persons, or their representatives, who are parties to the investigations.

Background

On March 31, 2016, Compass Chemical International LLC, Smyrna, Georgia, filed a petition with the Commission and Commerce, alleging that an industry in the United States is materially injured or threatened with material injury by reason of LTFV and subsidized imports of 1-hydroxyethylidene-1, 1-diphosphonic acid from China. Accordingly, effective March 31, 2016, the Commission, pursuant to sections 703(a) and 733(a) of the Tariff Act of 1930 (19 U.S.C. 1671b(a) and 1673b(a)), instituted countervailing duty investigation No. 701–TA–558 and antidumping duty investigation No. 703–TA–558 and 731–TA–1316 (Preliminary).

Notice of the institution of the Commission’s investigations and of a public conference to be held in connection therewith was given by posting copies of the notice in the Office of the Secretary, U.S. International Trade Commission, Washington, DC, and by publishing the notice in the Federal Register of April 7, 2016 (81 FR 20416). The conference was held in Washington, DC, on April 21, 2016, and all persons who requested the opportunity were permitted to appear in person or by counsel.

The Commission made these determinations pursuant to sections 703(a) and 733(a) of the Tariff Act of 1930 (19 U.S.C. 1671b(a) and 1673b(a)). It completed and filed its determinations in these investigations on May 16, 2016. The views of the Commission are contained in USITC Publication 4612 (May 2016), entitled 1-Hydroxyethylidene-1, 1-Diphosphonic Acid from China: Investigation Nos. 701–TA–558 and 731–TA–1316 (Preliminary).

By order of the Commission.
Issued: May 16, 2016.

Lisa R. Barton,
Secretary to the Commission.

[FR Doc. 2016–11939 Filed 5–19–16; 8:45 am]

DEPARTMENT OF JUSTICE

Drug Enforcement Administration

[DOCKET NO. DEA–392]

Manufacturer of Controlled Substances Registration: Pharmacore, Inc.

ACTION: Notice of registration.

SUMMARY: Pharmacore, Inc. applied to be registered as a manufacturer of certain basic classes of controlled substances. The Drug Enforcement Administration (DEA) grants Pharmacore, Inc. registration as a manufacturer of those controlled substances.

SUPPLEMENTARY INFORMATION: By notice dated January 27, 2016, and published in the Federal Register on February 4, 2016, 81 FR 6044, Pharmacore, Inc., 4180 Mendenhall Oaks Parkway, High Point, North Carolina 27265 applied to be registered as a manufacturer of certain basic classes of controlled substances. No comments or objections were submitted for this notice.

The DEA has considered the factors in 21 U.S.C. 823(a) and determined that the registration of Pharmacore, Inc. to manufacture the basic classes of controlled substances is consistent with the public interest and with United States obligations under international treaties, conventions, or protocols in effect on May 1, 1971. The DEA investigated the company’s maintenance of effective controls against diversion by inspecting and testing the company’s physical security systems, verifying the company’s compliance with state and local laws, and reviewing the company’s background and history.

Therefore, pursuant to 21 U.S.C. 823(a), and in accordance with 21 CFR 1301.33, the above-named company is granted registration as a bulk manufacturer of the following basic classes of controlled substances:

<table>
<thead>
<tr>
<th>Controlled substance</th>
<th>Schedule</th>
</tr>
</thead>
<tbody>
<tr>
<td>Oxymorphone (9652)</td>
<td>II</td>
</tr>
<tr>
<td>Noroxymorphone (9668)</td>
<td>II</td>
</tr>
</tbody>
</table>

The company plans to manufacture the listed controlled substances as active pharmaceutical ingredients (APIs) for clinical trials.

Dated: May 16, 2016.

Louis J. Milione,
Deputy Assistant Administrator.

[FR Doc. 2016–11939 Filed 5–19–16; 8:45 am]

BILLING CODE 4410–09–P

DEPARTMENT OF JUSTICE

Drug Enforcement Administration

[DOCKET NO. DEA–392]

Bulk Manufacturer of Controlled Substances Application: Mallinckrodt, LLC

ACTION: Notice of application.

DATES: Registered bulk manufacturers of the affected basic classes, and applicants therefore, may file written comments on or objections to the issuance of the proposed registration in accordance with 21 CFR 1301.33(a) on or before July 19, 2016.

ADDRESSES: Written comments should be sent to: Drug Enforcement Administration, Attention: DEA Federal Register Representative/ODW, 8701 Morrissette Drive, Springfield, Virginia 22152.

SUPPLEMENTARY INFORMATION: The Attorney General has delegated her authority under the Controlled Substances Act to the Administrator of the Drug Enforcement Administration (DEA), 28 CFR 0.100(b). Authority to exercise all necessary functions with respect to the promulgation and implementation of 21 CFR part 1301, incident to the registration of manufacturers, distributors, dispensers, importers, and exporters of controlled substances (other than final orders in connection with suspension, denial, or revocation of registration) has been redelegated to the Deputy Assistant Administrator of the DEA Office of Diversion Control (“Deputy Assistant Administrator”) pursuant to section 7 of 28 CFR part 0, appendix to subpart R.

In accordance with 21 CFR 1301.33(a), this is notice that on February 19, 2016, Mallinckrodt, LLC, 3600 North Second Street, Saint Louis, Missouri 63147 applied to be registered as a bulk manufacturer of the following basic classes of controlled substances:

<table>
<thead>
<tr>
<th>Controlled substance</th>
<th>Schedule</th>
</tr>
</thead>
<tbody>
<tr>
<td>Gamma Hydroxybutyric Acid (2010)</td>
<td></td>
</tr>
<tr>
<td>Tetrahydrocannabinols (7370)</td>
<td></td>
</tr>
<tr>
<td>Codeine-N-oxide (9053)</td>
<td></td>
</tr>
<tr>
<td>Dihydromorphine (9145)</td>
<td></td>
</tr>
<tr>
<td>Difenoxin (9168)</td>
<td></td>
</tr>
</tbody>
</table>